{
 "cells": [
  {
   "cell_type": "markdown",
   "source": [
    "## 文本分段工具"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Part 1:\n",
      "这里是你的长文本\n",
      "--------------------\n"
     ]
    }
   ],
   "source": [
    "def split_text(text, limit):\n",
    "    parts = []\n",
    "    while len(text) > limit:\n",
    "        part = text[:limit]\n",
    "        last_newline_pos = part.rfind('\\n')  # 可以让用户用两个换行符搞\n",
    "        if last_newline_pos >= 0:\n",
    "            part = part[:last_newline_pos]\n",
    "        parts.append(part)\n",
    "        text = text[len(part)+1:]  # +1 to skip the newline\n",
    "    parts.append(text)\n",
    "    return parts\n",
    "\n",
    "text = \"这里是你的长文本\"  # 请将此处替换为你的长文本\n",
    "split_parts = split_text(text, 4000)\n",
    "for i, part in enumerate(split_parts):\n",
    "    print(f\"Part {i+1}:\\n{part}\\n{'-'*20}\")\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:53:37.047619700Z",
     "start_time": "2023-06-17T06:53:37.022338500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "outputs": [],
   "source": [
    "txt = \"\"\"\n",
    "临床研究clinical trials，NCT05727839\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":357924,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT01198392\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"2005L02859\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
    "          \"Official Title\":\"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"August 2008\",\n",
    "          \"Overall Status\":\"Unknown status\",\n",
    "          \"LastKnownStatus\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"September 2008\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"December 2011\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"December 2011\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"September 1, 2010\",\n",
    "          \"Study First Submit QC Date\":\"September 9, 2010\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"September 10, 2010\",\n",
    "            \"Study First Post DateType\":\"Estimate\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"July 22, 2011\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"July 25, 2011\",\n",
    "            \"Last Update Post DateType\":\"Estimate\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyOldNameTitle\":\"Zhongzhen Guan ,Ruihua Xu\",\n",
    "            \"Responsible PartyOldOrganization\":\"Sun Yat-sen University Cancer Center\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"OversightHasDMC\":\"Yes\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
    "          \"Detailed Description\":\"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Gastric Cancer\"\n",
    "            ]\n",
    "          },\n",
    "          \"Keyword List\":{\n",
    "            \"Keyword\":[\n",
    "              \"gastric cancer\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 3\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"Randomized\",\n",
    "            \"DesignInterventionModel\":\"Parallel Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"270\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"S-1 plus cisplatin\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: s-1 plus cisplatin\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"Arm GroupLabel\":\"5-Fu plus cisplatin\",\n",
    "                \"Arm GroupType\":\"Active Comparator\",\n",
    "                \"Arm GroupDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: 5-Fu plus cisplatin\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"s-1 plus cisplatin\",\n",
    "                \"InterventionDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"S-1 plus cisplatin\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Tegafur,Gimeracil and Oteracil Potassium Capsules\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"5-Fu plus cisplatin\",\n",
    "                \"InterventionDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.\\n\\nNumber of Cycles: until progression or unacceptable toxicity develops.\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"5-Fu plus cisplatin\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"5-fluoroura\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Time to progression\",\n",
    "                \"Primary OutcomeTimeFrame\":\"The time from randomization until objective tumor progression or death\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Response rate\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 months\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease.\\nMale or female.\\nAge 18 -75.\\nPrevious chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study).\\nMeasurable disease, according to the Response Evaluation Criteria in Solid Tumours(RECIST)\\nECOG Performance status 0, 1 or 2\\nHaematological, Biochemical and Organ Function: Neutrophil count >2.0 × 10 9/L, platelet count > 100 ×10 9/L. Serum bilirubin< 1.5 × upper limit of normal (ULN); or, AST or ALT < 2.5 × ULN (or < 5 × ULN in patients with liver metastases); or, alkaline phosphatase< 2.5 × ULN (or > 5 × ULN in patients with liver metastases,Creatinine clearance > 60 mL/min.\\nSigned informed consent.\\n\\nExclusion Criteria:\\n\\nprior adjuvant/neoadjuvant therapy more than two regiments.\\nReceived any investigational drug treatment within 30 days of start of study treatment.\\nPatients with active gastrointestinal bleeding.\\nNeurological toxicity ≥ grade 2 NCI-CTCAE.\\nOther malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.\\nHistory or clinical evidence of brain metastases.\\nSerious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.\\nPregnancy women.\\nSubjects with reproductive potential not willing to use an effective method of contraception.\\nPatients with known active infection with HIV.\\nKnown hypersensitivity to any of the study drugs.\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"75 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Guan Zhongzhen, Professor\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"862087343565\",\n",
    "                \"CentralContactEMail\":\"guanzhzh@sysucc.org.cn\"\n",
    "              },{\n",
    "                \"CentralContactName\":\"Xu Ruihua, Professor\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"862087343228\",\n",
    "                \"CentralContactEMail\":\"xurh@sysucc.org.cn\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"RUIHUA XU, Professor\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Gangdong\",\n",
    "                \"LocationZip\":\"510060\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Guan Zhongzhen, Professor\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactPhone\":\"862087343565\",\n",
    "                      \"LocationContactEMail\":\"guanzhzh@sysucc.org.cn\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"References Module\":{\n",
    "          \"Reference List\":{\n",
    "            \"Reference\":[\n",
    "              {\n",
    "                \"ReferencePMID\":\"26439700\",\n",
    "                \"ReferenceType\":\"derived\",\n",
    "                \"ReferenceCitation\":\"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000013274\",\n",
    "                \"Condition MeshTerm\":\"Stomach Neoplasms\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000005770\",\n",
    "                \"Condition AncestorTerm\":\"Gastrointestinal Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000004067\",\n",
    "                \"Condition AncestorTerm\":\"Digestive System Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009371\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000004066\",\n",
    "                \"Condition AncestorTerm\":\"Digestive System Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000005767\",\n",
    "                \"Condition AncestorTerm\":\"Gastrointestinal Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000013272\",\n",
    "                \"Condition AncestorTerm\":\"Stomach Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M15216\",\n",
    "                \"Condition Browse LeafName\":\"Stomach Neoplasms\",\n",
    "                \"Condition Browse LeafAsFound\":\"Gastric Cancer\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8038\",\n",
    "                \"Condition Browse LeafName\":\"Gastrointestinal Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M6408\",\n",
    "                \"Condition Browse LeafName\":\"Digestive System Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8035\",\n",
    "                \"Condition Browse LeafName\":\"Gastrointestinal Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M6407\",\n",
    "                \"Condition Browse LeafName\":\"Digestive System Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M15214\",\n",
    "                \"Condition Browse LeafName\":\"Stomach Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T5486\",\n",
    "                \"Condition Browse LeafName\":\"Stomach Cancer\",\n",
    "                \"Condition Browse LeafAsFound\":\"Gastric Cancer\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC06\",\n",
    "                \"Condition Browse BranchName\":\"Digestive System Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Intervention Browse Module\":{\n",
    "          \"InterventionMeshList\":{\n",
    "            \"InterventionMesh\":[\n",
    "              {\n",
    "                \"InterventionMeshId\":\"D000002945\",\n",
    "                \"InterventionMeshTerm\":\"Cisplatin\"\n",
    "              },{\n",
    "                \"InterventionMeshId\":\"D000005641\",\n",
    "                \"InterventionMeshTerm\":\"Tegafur\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"InterventionAncestorList\":{\n",
    "            \"InterventionAncestor\":[\n",
    "              {\n",
    "                \"InterventionAncestorId\":\"D000000970\",\n",
    "                \"InterventionAncestorTerm\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"InterventionAncestorId\":\"D000000964\",\n",
    "                \"InterventionAncestorTerm\":\"Antimetabolites, Antineoplastic\"\n",
    "              },{\n",
    "                \"InterventionAncestorId\":\"D000000963\",\n",
    "                \"InterventionAncestorTerm\":\"Antimetabolites\"\n",
    "              },{\n",
    "                \"InterventionAncestorId\":\"D000045504\",\n",
    "                \"InterventionAncestorTerm\":\"Molecular Mechanisms of Pharmacological Action\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Leaf List\":{\n",
    "            \"Intervention Browse Leaf\":[\n",
    "              {\n",
    "                \"Intervention Browse LeafId\":\"M7912\",\n",
    "                \"Intervention Browse LeafName\":\"Tegafur\",\n",
    "                \"Intervention Browse LeafAsFound\":\"Lavage\",\n",
    "                \"Intervention Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M7752\",\n",
    "                \"Intervention Browse LeafName\":\"Fluorouracil\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M5334\",\n",
    "                \"Intervention Browse LeafName\":\"Cisplatin\",\n",
    "                \"Intervention Browse LeafAsFound\":\"Pain\",\n",
    "                \"Intervention Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M3433\",\n",
    "                \"Intervention Browse LeafName\":\"Antimetabolites\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Branch List\":{\n",
    "            \"Intervention Browse Branch\":[\n",
    "              {\n",
    "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
    "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
    "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT:NCT03544905.json\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":178364,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT03544905\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"CYH33-101\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Haihe Biopharma Co., Ltd.\",\n",
    "            \"Org Class\":\"INDUSTRY\"\n",
    "          },\n",
    "          \"Brief Title\":\"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
    "          \"Official Title\":\"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"January 2023\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"July 5, 2018\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"June 30, 2023\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"March 31, 2024\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"May 22, 2018\",\n",
    "          \"Study First Submit QC Date\":\"May 22, 2018\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"June 4, 2018\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"January 4, 2023\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"January 6, 2023\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Sponsor\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Haihe Biopharma Co., Ltd.\",\n",
    "            \"Lead SponsorClass\":\"INDUSTRY\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"OversightHasDMC\":\"Yes\",\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
    "          \"Detailed Description\":\"This study includes Phase Ia and Phase Ib.\\n\\nIn the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\\n\\nIn Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Advanced Solid Tumors\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 1\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"N/A\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"100\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Dose escalation study of CYH33\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"To determine the maximum tolerated dose (MTD) of CYH33\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: CYH33 for tablet\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"CYH33 for tablet\",\n",
    "                \"InterventionDescription\":\"1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Dose escalation study of CYH33\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"MTD(Max tolerance does)\",\n",
    "                \"Primary OutcomeDescription\":\"To evaluate the MTD in patients with advanced solid tumor\",\n",
    "                \"Primary OutcomeTimeFrame\":\"35 days\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nmain inclusion:\\n\\nEvidence of a personally signed informed consent document;\\nMale and/or female subjects above the ages of 18 years;\\nLocally advanced or metastatic solid tumor patients who have failed or relapsed on current standard of care for Phase 1a;\\nSubject may provide Tumor tissue section(at least 8 pieces) if they agree;\\nECOG performance score 0-1;\\nLife expectancy ≥ 12 weeks;\\nAt least 1 measurable target lesion on the baseline scan as per RECIST 1.1\\n\\nExclusion Criteria:\\n\\nmain criteria:\\n\\nprior received anti-tumor treatment, including anticancer drugs for the treatment within 28 days of first dose of study treatment;\\nPrior or concomitant other malignant tumor;\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Ruihua Xu, M.D\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"86-20-87343804\",\n",
    "                \"CentralContactEMail\":\"ruihxu@163.com\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Ruihua Xu, M.D\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Guangdong\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Xu Ruihua, MD\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactPhone\":\"13922206676\",\n",
    "                      \"LocationContactEMail\":\"xurh@sysucc.org.cn\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT:NCT05727839.json\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":10726,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT05727839\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"JCXH-211-003\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Immorna Biotherapeutics, Inc.\",\n",
    "            \"Org Class\":\"INDUSTRY\"\n",
    "          },\n",
    "          \"Brief Title\":\"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
    "          \"Official Title\":\"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"March 2023\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"February 24, 2023\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"July 24, 2025\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"August 24, 2025\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"February 1, 2023\",\n",
    "          \"Study First Submit QC Date\":\"February 6, 2023\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"February 14, 2023\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"March 16, 2023\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"March 20, 2023\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Sponsor\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Immorna Biotherapeutics, Inc.\",\n",
    "            \"Lead SponsorClass\":\"INDUSTRY\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
    "          \"Detailed Description\":\"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\\n\\n1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Cutaneous Tumor\",\n",
    "              \"Malignant Solid Tumor\"\n",
    "            ]\n",
    "          },\n",
    "          \"Keyword List\":{\n",
    "            \"Keyword\":[\n",
    "              \"Tumor\",\n",
    "              \"Intratumoral injection\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 1\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"Non-Randomized\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"156\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Phase Ia:Dose escalation\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"JCXH-211 will be delivered by intratumoral injection in 2 stages:\\n\\n（Part1）Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results,1-2 dose groups were selected for deep lesion injection study, dose escalation will follow the \\\"3 + 3\\\" principle.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: JCXH-211 Injection\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"Arm GroupLabel\":\"Phase Ib: Dose Extension\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase Ia.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: JCXH-211 Injection\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"JCXH-211 Injection\",\n",
    "                \"InterventionDescription\":\"JCXH-211 administered once every 28 days\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Phase Ia:Dose escalation\",\n",
    "                    \"Phase Ib: Dose Extension\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Intratumoral injection\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Dose limiting toxicity\",\n",
    "                \"Primary OutcomeDescription\":\"Dose limiting toxicity, evaluated in the Phase Ia, which will be used to determine the MTD and to determine dose escalation.\",\n",
    "                \"Primary OutcomeTimeFrame\":\"Within 28 days after the first dose\"\n",
    "              },{\n",
    "                \"Primary Outcome Measure\":\"Incidence of adverse events （Safety and Tolerability）\",\n",
    "                \"Primary OutcomeDescription\":\"Safety and tolerability as determined by the incidence of adverse events （AEs）, including severe AEs and serious AEs （SAEs）.\",\n",
    "                \"Primary OutcomeTimeFrame\":\"From consent to 28 days after the last dose of study drug\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Objective response rate （ORR）\",\n",
    "                \"Secondary OutcomeDescription\":\"Objective response rate is defined as the proportion of patients that achieve a complete response （CR） or partial response （PR） during the study participation.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Duration of response （DoR）\",\n",
    "                \"Secondary OutcomeDescription\":\"Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months following first reported response\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Disease control rate （DCR）\",\n",
    "                \"Secondary OutcomeDescription\":\"Disease control rate is defined as the proportion of patients with CR or PR or stable disease （SD） with the DoR ≥ 12weeks observed from Day 1 to disease progression.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Time to response （TTR）\",\n",
    "                \"Secondary OutcomeDescription\":\"Time to response is defined as the time from Day 1 until the first documentation of objective response （CR or PR）.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months from the start of study therapy\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Progression-free survival （PFS）\",\n",
    "                \"Secondary OutcomeDescription\":\"Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Overall survival （OS）\",\n",
    "                \"Secondary OutcomeDescription\":\"Overall survival is defined as the time from Day 1 until death due to any cause.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 24 months\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nMale or female patients 18-75\\nPatients with malignant solid tumors that have been diagnosed by pathology and/or cytology\\nPatients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist\\nPatients with at least one non-injected measurable tumor lesion per RECIST v1.1\\nPatients with lesions suitable for intratumoral injection (the lesion length is at least 10mm and not exceeding 80mm)\\nPatients enrolled in the Skin/subcutaneous lesions and deep （visceral） lesions stages of Phase Ia must agree to provide pre- and post-treatment tumor biopsy tissues\\nPatients must have adequate organ and marrow functions\\nPatients with treated brain metastases are eligible if meeting protocol's requirement\\nPatients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy\\n\\nExclusion Criteria:\\n\\nPatients who have received prior IL-12 either alone or as part of a treatment regimen\\nPatients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)\\nPatients requiring therapeutic doses of anticoagulation\\nPatients with tumors that impinge on major airways, blood vessels, or nerve bundles\\nPatients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications\\nPatients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment\\nCurrent or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment\\nPatient with history of solid organ or allogenic bone marrow transplantation\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"75 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qi Wang\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"+8613381113913\",\n",
    "                \"CentralContactEMail\":\"qi.wang@immorna.com\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Xu ruihua, President\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangdong\",\n",
    "                \"LocationState\":\"Guangzhou\",\n",
    "                \"LocationZip\":\"510060\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Xu R hua, professor\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactEMail\":\"ruihxu@163.com\"\n",
    "                    },{\n",
    "                      \"LocationContactName\":\"ruan dan yun, physician\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactPhone\":\"13760611470\",\n",
    "                      \"LocationContactEMail\":\"ruandy1@sysucc.org.cn\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000009369\",\n",
    "                \"Condition MeshTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000012878\",\n",
    "                \"Condition MeshTerm\":\"Skin Neoplasms\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009371\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000012871\",\n",
    "                \"Condition AncestorTerm\":\"Skin Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M14833\",\n",
    "                \"Condition Browse LeafName\":\"Skin Neoplasms\",\n",
    "                \"Condition Browse LeafAsFound\":\"Cutaneous Tumors\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M14826\",\n",
    "                \"Condition Browse LeafName\":\"Skin Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC17\",\n",
    "                \"Condition Browse BranchName\":\"Skin and Connective Tissue Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:55:26.388649Z",
     "start_time": "2023-06-17T06:55:26.373027800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Part 1:\n",
      "\n",
      "临床研究clinical trials，NCT05727839\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":357924,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT01198392\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"2005L02859\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "          \"Official Title\":\"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"August 2008\",\n",
      "          \"Overall Status\":\"Unknown status\",\n",
      "          \"LastKnownStatus\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"September 2008\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"December 2011\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"December 2011\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"September 1, 2010\",\n",
      "          \"Study First Submit QC Date\":\"September 9, 2010\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"September 10, 2010\",\n",
      "            \"Study First Post DateType\":\"Estimate\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"July 22, 2011\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"July 25, 2011\",\n",
      "            \"Last Update Post DateType\":\"Estimate\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyOldNameTitle\":\"Zhongzhen Guan ,Ruihua Xu\",\n",
      "            \"Responsible PartyOldOrganization\":\"Sun Yat-sen University Cancer Center\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"OversightHasDMC\":\"Yes\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "          \"Detailed Description\":\"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Gastric Cancer\"\n",
      "            ]\n",
      "          },\n",
      "          \"Keyword List\":{\n",
      "            \"Keyword\":[\n",
      "              \"gastric cancer\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 3\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Randomized\",\n",
      "            \"DesignInterventionModel\":\"Parallel Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"270\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"S-1 plus cisplatin\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
      "--------------------\n",
      "Part 2:\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: s-1 plus cisplatin\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"5-Fu plus cisplatin\",\n",
      "                \"Arm GroupType\":\"Active Comparator\",\n",
      "                \"Arm GroupDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: 5-Fu plus cisplatin\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"s-1 plus cisplatin\",\n",
      "                \"InterventionDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"S-1 plus cisplatin\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Tegafur,Gimeracil and Oteracil Potassium Capsules\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"5-Fu plus cisplatin\",\n",
      "                \"InterventionDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.\n",
      "\n",
      "Number of Cycles: until progression or unacceptable toxicity develops.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"5-Fu plus cisplatin\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"5-fluoroura\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Time to progression\",\n",
      "                \"Primary OutcomeTimeFrame\":\"The time from randomization until objective tumor progression or death\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Response rate\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 months\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease.\n",
      "Male or female.\n",
      "Age 18 -75.\n",
      "Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study).\n",
      "Measurable disease, according to the Response Evaluation Criteria in Solid Tumours(RECIST)\n",
      "ECOG Performance status 0, 1 or 2\n",
      "Haematological, Biochemical and Organ Function: Neutrophil count >2.0 × 10 9/L, platelet count > 100 ×10 9/L. Serum bilirubin< 1.5 × upper limit of normal (ULN); or, AST or ALT < 2.5 × ULN (or < 5 × ULN in patients with liver metastases); or, alkaline phosphatase< 2.5 × ULN (or > 5 × ULN in patients with liver metastases,Creatinine clearance > 60 mL/min.\n",
      "Signed informed consent.\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "prior adjuvant/neoadjuvant therapy more than two regiments.\n",
      "Received any investigational drug treatment within 30 days of start of study treatment.\n",
      "--------------------\n",
      "Part 3:\n",
      "Patients with active gastrointestinal bleeding.\n",
      "Neurological toxicity ≥ grade 2 NCI-CTCAE.\n",
      "Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.\n",
      "History or clinical evidence of brain metastases.\n",
      "Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.\n",
      "Pregnancy women.\n",
      "Subjects with reproductive potential not willing to use an effective method of contraception.\n",
      "Patients with known active infection with HIV.\n",
      "Known hypersensitivity to any of the study drugs.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Guan Zhongzhen, Professor\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"862087343565\",\n",
      "                \"CentralContactEMail\":\"guanzhzh@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Xu Ruihua, Professor\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"862087343228\",\n",
      "                \"CentralContactEMail\":\"xurh@sysucc.org.cn\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"RUIHUA XU, Professor\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Gangdong\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Guan Zhongzhen, Professor\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"862087343565\",\n",
      "                      \"LocationContactEMail\":\"guanzhzh@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"References Module\":{\n",
      "          \"Reference List\":{\n",
      "            \"Reference\":[\n",
      "              {\n",
      "                \"ReferencePMID\":\"26439700\",\n",
      "                \"ReferenceType\":\"derived\",\n",
      "                \"ReferenceCitation\":\"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000013274\",\n",
      "                \"Condition MeshTerm\":\"Stomach Neoplasms\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000005770\",\n",
      "                \"Condition AncestorTerm\":\"Gastrointestinal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000004067\",\n",
      "                \"Condition AncestorTerm\":\"Digestive System Neoplasms\"\n",
      "--------------------\n",
      "Part 4:\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000004066\",\n",
      "                \"Condition AncestorTerm\":\"Digestive System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000005767\",\n",
      "                \"Condition AncestorTerm\":\"Gastrointestinal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000013272\",\n",
      "                \"Condition AncestorTerm\":\"Stomach Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M15216\",\n",
      "                \"Condition Browse LeafName\":\"Stomach Neoplasms\",\n",
      "                \"Condition Browse LeafAsFound\":\"Gastric Cancer\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8038\",\n",
      "                \"Condition Browse LeafName\":\"Gastrointestinal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M6408\",\n",
      "                \"Condition Browse LeafName\":\"Digestive System Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8035\",\n",
      "                \"Condition Browse LeafName\":\"Gastrointestinal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M6407\",\n",
      "                \"Condition Browse LeafName\":\"Digestive System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M15214\",\n",
      "                \"Condition Browse LeafName\":\"Stomach Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T5486\",\n",
      "                \"Condition Browse LeafName\":\"Stomach Cancer\",\n",
      "                \"Condition Browse LeafAsFound\":\"Gastric Cancer\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC06\",\n",
      "                \"Condition Browse BranchName\":\"Digestive System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"InterventionMeshList\":{\n",
      "            \"InterventionMesh\":[\n",
      "              {\n",
      "                \"InterventionMeshId\":\"D000002945\",\n",
      "                \"InterventionMeshTerm\":\"Cisplatin\"\n",
      "              },{\n",
      "                \"InterventionMeshId\":\"D000005641\",\n",
      "                \"InterventionMeshTerm\":\"Tegafur\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"InterventionAncestorList\":{\n",
      "            \"InterventionAncestor\":[\n",
      "              {\n",
      "                \"InterventionAncestorId\":\"D000000970\",\n",
      "                \"InterventionAncestorTerm\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"InterventionAncestorId\":\"D000000964\",\n",
      "                \"InterventionAncestorTerm\":\"Antimetabolites, Antineoplastic\"\n",
      "              },{\n",
      "                \"InterventionAncestorId\":\"D000000963\",\n",
      "                \"InterventionAncestorTerm\":\"Antimetabolites\"\n",
      "              },{\n",
      "                \"InterventionAncestorId\":\"D000045504\",\n",
      "--------------------\n",
      "Part 5:\n",
      "                \"InterventionAncestorTerm\":\"Molecular Mechanisms of Pharmacological Action\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M7912\",\n",
      "                \"Intervention Browse LeafName\":\"Tegafur\",\n",
      "                \"Intervention Browse LeafAsFound\":\"Lavage\",\n",
      "                \"Intervention Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M7752\",\n",
      "                \"Intervention Browse LeafName\":\"Fluorouracil\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M5334\",\n",
      "                \"Intervention Browse LeafName\":\"Cisplatin\",\n",
      "                \"Intervention Browse LeafAsFound\":\"Pain\",\n",
      "                \"Intervention Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M3433\",\n",
      "                \"Intervention Browse LeafName\":\"Antimetabolites\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT:NCT03544905.json\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":178364,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT03544905\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"CYH33-101\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Haihe Biopharma Co., Ltd.\",\n",
      "            \"Org Class\":\"INDUSTRY\"\n",
      "          },\n",
      "          \"Brief Title\":\"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "          \"Official Title\":\"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"January 2023\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"July 5, 2018\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"June 30, 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"March 31, 2024\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"May 22, 2018\",\n",
      "          \"Study First Submit QC Date\":\"May 22, 2018\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"June 4, 2018\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"January 4, 2023\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"January 6, 2023\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Sponsor\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Haihe Biopharma Co., Ltd.\",\n",
      "            \"Lead SponsorClass\":\"INDUSTRY\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"OversightHasDMC\":\"Yes\",\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "--------------------\n",
      "Part 6:\n",
      "          \"Brief Summary\":\"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "          \"Detailed Description\":\"This study includes Phase Ia and Phase Ib.\n",
      "\n",
      "In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "\n",
      "In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Advanced Solid Tumors\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 1\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"100\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Dose escalation study of CYH33\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"To determine the maximum tolerated dose (MTD) of CYH33\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: CYH33 for tablet\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"CYH33 for tablet\",\n",
      "                \"InterventionDescription\":\"1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Dose escalation study of CYH33\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"MTD(Max tolerance does)\",\n",
      "                \"Primary OutcomeDescription\":\"To evaluate the MTD in patients with advanced solid tumor\",\n",
      "                \"Primary OutcomeTimeFrame\":\"35 days\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "main inclusion:\n",
      "\n",
      "Evidence of a personally signed informed consent document;\n",
      "Male and/or female subjects above the ages of 18 years;\n",
      "--------------------\n",
      "Part 7:\n",
      "Locally advanced or metastatic solid tumor patients who have failed or relapsed on current standard of care for Phase 1a;\n",
      "Subject may provide Tumor tissue section(at least 8 pieces) if they agree;\n",
      "ECOG performance score 0-1;\n",
      "Life expectancy ≥ 12 weeks;\n",
      "At least 1 measurable target lesion on the baseline scan as per RECIST 1.1\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "main criteria:\n",
      "\n",
      "prior received anti-tumor treatment, including anticancer drugs for the treatment within 28 days of first dose of study treatment;\n",
      "Prior or concomitant other malignant tumor;\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Ruihua Xu, M.D\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"86-20-87343804\",\n",
      "                \"CentralContactEMail\":\"ruihxu@163.com\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Ruihua Xu, M.D\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Xu Ruihua, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"13922206676\",\n",
      "                      \"LocationContactEMail\":\"xurh@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT:NCT05727839.json\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":10726,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT05727839\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"JCXH-211-003\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Immorna Biotherapeutics, Inc.\",\n",
      "            \"Org Class\":\"INDUSTRY\"\n",
      "          },\n",
      "          \"Brief Title\":\"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "          \"Official Title\":\"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2023\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"February 24, 2023\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"July 24, 2025\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"August 24, 2025\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"February 1, 2023\",\n",
      "          \"Study First Submit QC Date\":\"February 6, 2023\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"February 14, 2023\",\n",
      "--------------------\n",
      "Part 8:\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 16, 2023\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 20, 2023\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Sponsor\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Immorna Biotherapeutics, Inc.\",\n",
      "            \"Lead SponsorClass\":\"INDUSTRY\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "          \"Detailed Description\":\"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "\n",
      "1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Cutaneous Tumor\",\n",
      "              \"Malignant Solid Tumor\"\n",
      "            ]\n",
      "          },\n",
      "          \"Keyword List\":{\n",
      "            \"Keyword\":[\n",
      "              \"Tumor\",\n",
      "              \"Intratumoral injection\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 1\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Non-Randomized\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"156\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Phase Ia:Dose escalation\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"JCXH-211 will be delivered by intratumoral injection in 2 stages:\n",
      "\n",
      "（Part1）Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results,1-2 dose groups were selected for deep lesion injection study, dose escalation will follow the \"3 + 3\" principle.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: JCXH-211 Injection\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"Phase Ib: Dose Extension\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase Ia.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: JCXH-211 Injection\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"JCXH-211 Injection\",\n",
      "--------------------\n",
      "Part 9:\n",
      "                \"InterventionDescription\":\"JCXH-211 administered once every 28 days\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Phase Ia:Dose escalation\",\n",
      "                    \"Phase Ib: Dose Extension\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Intratumoral injection\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Dose limiting toxicity\",\n",
      "                \"Primary OutcomeDescription\":\"Dose limiting toxicity, evaluated in the Phase Ia, which will be used to determine the MTD and to determine dose escalation.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"Within 28 days after the first dose\"\n",
      "              },{\n",
      "                \"Primary Outcome Measure\":\"Incidence of adverse events （Safety and Tolerability）\",\n",
      "                \"Primary OutcomeDescription\":\"Safety and tolerability as determined by the incidence of adverse events （AEs）, including severe AEs and serious AEs （SAEs）.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"From consent to 28 days after the last dose of study drug\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Objective response rate （ORR）\",\n",
      "                \"Secondary OutcomeDescription\":\"Objective response rate is defined as the proportion of patients that achieve a complete response （CR） or partial response （PR） during the study participation.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Duration of response （DoR）\",\n",
      "                \"Secondary OutcomeDescription\":\"Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months following first reported response\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Disease control rate （DCR）\",\n",
      "                \"Secondary OutcomeDescription\":\"Disease control rate is defined as the proportion of patients with CR or PR or stable disease （SD） with the DoR ≥ 12weeks observed from Day 1 to disease progression.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Time to response （TTR）\",\n",
      "                \"Secondary OutcomeDescription\":\"Time to response is defined as the time from Day 1 until the first documentation of objective response （CR or PR）.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months from the start of study therapy\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Progression-free survival （PFS）\",\n",
      "                \"Secondary OutcomeDescription\":\"Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 12 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall survival （OS）\",\n",
      "                \"Secondary OutcomeDescription\":\"Overall survival is defined as the time from Day 1 until death due to any cause.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 24 months\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Male or female patients 18-75\n",
      "Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology\n",
      "Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist\n",
      "--------------------\n",
      "Part 10:\n",
      "Patients with at least one non-injected measurable tumor lesion per RECIST v1.1\n",
      "Patients with lesions suitable for intratumoral injection (the lesion length is at least 10mm and not exceeding 80mm)\n",
      "Patients enrolled in the Skin/subcutaneous lesions and deep （visceral） lesions stages of Phase Ia must agree to provide pre- and post-treatment tumor biopsy tissues\n",
      "Patients must have adequate organ and marrow functions\n",
      "Patients with treated brain metastases are eligible if meeting protocol's requirement\n",
      "Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "Patients who have received prior IL-12 either alone or as part of a treatment regimen\n",
      "Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)\n",
      "Patients requiring therapeutic doses of anticoagulation\n",
      "Patients with tumors that impinge on major airways, blood vessels, or nerve bundles\n",
      "Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications\n",
      "Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment\n",
      "Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment\n",
      "Patient with history of solid organ or allogenic bone marrow transplantation\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qi Wang\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"+8613381113913\",\n",
      "                \"CentralContactEMail\":\"qi.wang@immorna.com\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Xu ruihua, President\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangdong\",\n",
      "                \"LocationState\":\"Guangzhou\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Xu R hua, professor\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactEMail\":\"ruihxu@163.com\"\n",
      "                    },{\n",
      "                      \"LocationContactName\":\"ruan dan yun, physician\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"13760611470\",\n",
      "                      \"LocationContactEMail\":\"ruandy1@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000009369\",\n",
      "                \"Condition MeshTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000012878\",\n",
      "--------------------\n",
      "Part 11:\n",
      "                \"Condition MeshTerm\":\"Skin Neoplasms\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000012871\",\n",
      "                \"Condition AncestorTerm\":\"Skin Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M14833\",\n",
      "                \"Condition Browse LeafName\":\"Skin Neoplasms\",\n",
      "                \"Condition Browse LeafAsFound\":\"Cutaneous Tumors\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M14826\",\n",
      "                \"Condition Browse LeafName\":\"Skin Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC17\",\n",
      "                \"Condition Browse BranchName\":\"Skin and Connective Tissue Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "\n",
      "\n",
      "--------------------\n"
     ]
    }
   ],
   "source": [
    "split_parts = split_text(txt, 4000)\n",
    "for i, part in enumerate(split_parts):\n",
    "    print(f\"Part {i+1}:\\n{part}\\n{'-'*20}\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:55:34.059339600Z",
     "start_time": "2023-06-17T06:55:34.043688200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "outputs": [
    {
     "data": {
      "text/plain": "'\\n临床研究clinical trials，NCT05727839\\n{\\n  \"Full Study\":{\\n    \"Rank\":357924,\\n    \"Study\":{\\n      \"Protocol Section\":{\\n        \"Identification Module\":{\\n          \"NCT Id\":\"NCT01198392\",\\n          \"Org Study Id Info\":{\\n            \"Org Study Id\":\"2005L02859\"\\n          },\\n          \"Organization\":{\\n            \"Org Full Name\":\"Sun Yat-sen University\",\\n            \"Org Class\":\"OTHER\"\\n          },\\n          \"Brief Title\":\"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\\n          \"Official Title\":\"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\"\\n        },\\n        \"Status Module\":{\\n          \"Status Verified Date\":\"August 2008\",\\n          \"Overall Status\":\"Unknown status\",\\n          \"LastKnownStatus\":\"Recruiting\",\\n          \"Expanded Access Info\":{\\n            \"Has Expanded Access\":\"No\"\\n          },\\n          \"Start Date Struct\":{\\n            \"Start Date\":\"September 2008\"\\n          },\\n          \"Primary Completion Date Struct\":{\\n            \"Primary Completion Date\":\"December 2011\",\\n            \"Primary Completion DateType\":\"Anticipated\"\\n          },\\n          \"Completion Date Struct\":{\\n            \"Completion Date\":\"December 2011\",\\n            \"Completion DateType\":\"Anticipated\"\\n          },\\n          \"Study First Submit Date\":\"September 1, 2010\",\\n          \"Study First Submit QC Date\":\"September 9, 2010\",\\n          \"Study First Post Date Struct\":{\\n            \"Study First Post Date\":\"September 10, 2010\",\\n            \"Study First Post DateType\":\"Estimate\"\\n          },\\n          \"Last Update Submit Date\":\"July 22, 2011\",\\n          \"Last Update Post Date Struct\":{\\n            \"Last Update Post Date\":\"July 25, 2011\",\\n            \"Last Update Post DateType\":\"Estimate\"\\n          }\\n        },\\n        \"Sponsor Collaborators Module\":{\\n          \"Responsible Party\":{\\n            \"Responsible PartyOldNameTitle\":\"Zhongzhen Guan ,Ruihua Xu\",\\n            \"Responsible PartyOldOrganization\":\"Sun Yat-sen University Cancer Center\"\\n          },\\n          \"Lead Sponsor\":{\\n            \"Lead SponsorName\":\"Sun Yat-sen University\",\\n            \"Lead SponsorClass\":\"OTHER\"\\n          }\\n        },\\n        \"Oversight Module\":{\\n          \"OversightHasDMC\":\"Yes\"\\n        },\\n        \"Description Module\":{\\n          \"Brief Summary\":\"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\\n          \"Detailed Description\":\"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\"\\n        },\\n        \"Conditions Module\":{\\n          \"Condition List\":{\\n            \"Condition\":[\\n              \"Gastric Cancer\"\\n            ]\\n          },\\n          \"Keyword List\":{\\n            \"Keyword\":[\\n              \"gastric cancer\"\\n            ]\\n          }\\n        },\\n        \"Design Module\":{\\n          \"Study Type\":\"Interventional\",\\n          \"PhaseList\":{\\n            \"Phase\":[\\n              \"Phase 3\"\\n            ]\\n          },\\n          \"Design Info\":{\\n            \"DesignAllocation\":\"Randomized\",\\n            \"DesignInterventionModel\":\"Parallel Assignment\",\\n            \"DesignPrimaryPurpose\":\"Treatment\",\\n            \"DesignMaskingInfo\":{\\n              \"DesignMasking\":\"None (Open Label)\"\\n            }\\n          },\\n          \"Enrollment Info\":{\\n            \"Enrollment Count\":\"270\",\\n            \"Enrollment Type\":\"Anticipated\"\\n          }\\n        },\\n        \"Arms Interventions Module\":{\\n          \"Arm Group List\":{\\n            \"Arm Group\":[\\n              {\\n                \"Arm GroupLabel\":\"S-1 plus cisplatin\",\\n                \"Arm GroupType\":\"Experimental\",\\n                \"Arm GroupDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",'"
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "split_parts[0]"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:56:05.148428900Z",
     "start_time": "2023-06-17T06:56:05.101552400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "outputs": [
    {
     "data": {
      "text/plain": "'                \"Arm GroupIntervention List\":{\\n                  \"Arm GroupInterventionName\":[\\n                    \"Drug: s-1 plus cisplatin\"\\n                  ]\\n                }\\n              },{\\n                \"Arm GroupLabel\":\"5-Fu plus cisplatin\",\\n                \"Arm GroupType\":\"Active Comparator\",\\n                \"Arm GroupDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.\",\\n                \"Arm GroupIntervention List\":{\\n                  \"Arm GroupInterventionName\":[\\n                    \"Drug: 5-Fu plus cisplatin\"\\n                  ]\\n                }\\n              }\\n            ]\\n          },\\n          \"Intervention List\":{\\n            \"Intervention\":[\\n              {\\n                \"InterventionType\":\"Drug\",\\n                \"InterventionName\":\"s-1 plus cisplatin\",\\n                \"InterventionDescription\":\"S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.\",\\n                \"InterventionArm GroupLabelList\":{\\n                  \"InterventionArm GroupLabel\":[\\n                    \"S-1 plus cisplatin\"\\n                  ]\\n                },\\n                \"InterventionOtherNameList\":{\\n                  \"InterventionOtherName\":[\\n                    \"Tegafur,Gimeracil and Oteracil Potassium Capsules\"\\n                  ]\\n                }\\n              },{\\n                \"InterventionType\":\"Drug\",\\n                \"InterventionName\":\"5-Fu plus cisplatin\",\\n                \"InterventionDescription\":\"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.\\n\\nNumber of Cycles: until progression or unacceptable toxicity develops.\",\\n                \"InterventionArm GroupLabelList\":{\\n                  \"InterventionArm GroupLabel\":[\\n                    \"5-Fu plus cisplatin\"\\n                  ]\\n                },\\n                \"InterventionOtherNameList\":{\\n                  \"InterventionOtherName\":[\\n                    \"5-fluoroura\"\\n                  ]\\n                }\\n              }\\n            ]\\n          }\\n        },\\n        \"Outcomes Module\":{\\n          \"Primary Outcome List\":{\\n            \"Primary Outcome\":[\\n              {\\n                \"Primary Outcome Measure\":\"Time to progression\",\\n                \"Primary OutcomeTimeFrame\":\"The time from randomization until objective tumor progression or death\"\\n              }\\n            ]\\n          },\\n          \"Secondary Outcome List\":{\\n            \"Secondary Outcome\":[\\n              {\\n                \"Secondary Outcome Measure\":\"Response rate\",\\n                \"Secondary OutcomeTimeFrame\":\"2 months\"\\n              }\\n            ]\\n          }\\n        },\\n        \"Eligibility Module\":{\\n          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease.\\nMale or female.\\nAge 18 -75.\\nPrevious chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study).\\nMeasurable disease, according to the Response Evaluation Criteria in Solid Tumours(RECIST)\\nECOG Performance status 0, 1 or 2\\nHaematological, Biochemical and Organ Function: Neutrophil count >2.0 × 10 9/L, platelet count > 100 ×10 9/L. Serum bilirubin< 1.5 × upper limit of normal (ULN); or, AST or ALT < 2.5 × ULN (or < 5 × ULN in patients with liver metastases); or, alkaline phosphatase< 2.5 × ULN (or > 5 × ULN in patients with liver metastases,Creatinine clearance > 60 mL/min.\\nSigned informed consent.\\n\\nExclusion Criteria:\\n\\nprior adjuvant/neoadjuvant therapy more than two regiments.\\nReceived any investigational drug treatment within 30 days of start of study treatment.'"
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "split_parts[1]\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:56:18.217078700Z",
     "start_time": "2023-06-17T06:56:18.170179800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "outputs": [
    {
     "data": {
      "text/plain": "'Patients with active gastrointestinal bleeding.\\nNeurological toxicity ≥ grade 2 NCI-CTCAE.\\nOther malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.\\nHistory or clinical evidence of brain metastases.\\nSerious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.\\nPregnancy women.\\nSubjects with reproductive potential not willing to use an effective method of contraception.\\nPatients with known active infection with HIV.\\nKnown hypersensitivity to any of the study drugs.\",\\n          \"Healthy Volunteers\":\"No\",\\n          \"Gender\":\"All\",\\n          \"Minimum Age\":\"18 Years\",\\n          \"MaximumAge\":\"75 Years\",\\n          \"Std Age List\":{\\n            \"Std Age\":[\\n              \"Adult\",\\n              \"Older Adult\"\\n            ]\\n          }\\n        },\\n        \"Contacts Locations Module\":{\\n          \"CentralContactList\":{\\n            \"CentralContact\":[\\n              {\\n                \"CentralContactName\":\"Guan Zhongzhen, Professor\",\\n                \"CentralContactRole\":\"Contact\",\\n                \"CentralContactPhone\":\"862087343565\",\\n                \"CentralContactEMail\":\"guanzhzh@sysucc.org.cn\"\\n              },{\\n                \"CentralContactName\":\"Xu Ruihua, Professor\",\\n                \"CentralContactRole\":\"Contact\",\\n                \"CentralContactPhone\":\"862087343228\",\\n                \"CentralContactEMail\":\"xurh@sysucc.org.cn\"\\n              }\\n            ]\\n          },\\n          \"Overall Official List\":{\\n            \"Overall Official\":[\\n              {\\n                \"Overall OfficialName\":\"RUIHUA XU, Professor\",\\n                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\\n                \"Overall OfficialRole\":\"Principal Investigator\"\\n              }\\n            ]\\n          },\\n          \"Location List\":{\\n            \"Location\":[\\n              {\\n                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\\n                \"LocationStatus\":\"Recruiting\",\\n                \"LocationCity\":\"Guangzhou\",\\n                \"LocationState\":\"Gangdong\",\\n                \"LocationZip\":\"510060\",\\n                \"LocationCountry\":\"China\",\\n                \"LocationContactList\":{\\n                  \"LocationContact\":[\\n                    {\\n                      \"LocationContactName\":\"Guan Zhongzhen, Professor\",\\n                      \"LocationContactRole\":\"Contact\",\\n                      \"LocationContactPhone\":\"862087343565\",\\n                      \"LocationContactEMail\":\"guanzhzh@sysucc.org.cn\"\\n                    }\\n                  ]\\n                }\\n              }\\n            ]\\n          }\\n        },\\n        \"References Module\":{\\n          \"Reference List\":{\\n            \"Reference\":[\\n              {\\n                \"ReferencePMID\":\"26439700\",\\n                \"ReferenceType\":\"derived\",\\n                \"ReferenceCitation\":\"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\"\\n              }\\n            ]\\n          }\\n        }\\n      },\\n      \"Derived Section\":{\\n        \"Misc Info Module\":{\\n          \"Version Holder\":\"May 19, 2023\"\\n        },\\n        \"Condition Browse Module\":{\\n          \"Condition Mesh List\":{\\n            \"Condition Mesh\":[\\n              {\\n                \"Condition MeshId\":\"D000013274\",\\n                \"Condition MeshTerm\":\"Stomach Neoplasms\"\\n              }\\n            ]\\n          },\\n          \"Condition Ancestor List\":{\\n            \"Condition Ancestor\":[\\n              {\\n                \"Condition AncestorId\":\"D000005770\",\\n                \"Condition AncestorTerm\":\"Gastrointestinal Neoplasms\"\\n              },{\\n                \"Condition AncestorId\":\"D000004067\",\\n                \"Condition AncestorTerm\":\"Digestive System Neoplasms\"'"
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "split_parts[2]"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T06:56:34.059858400Z",
     "start_time": "2023-06-17T06:56:34.044232500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "outputs": [],
   "source": [
    "d1={'a':1,'b':2,'c':''}"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:00:56.860184400Z",
     "start_time": "2023-06-17T07:00:56.844588800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "outputs": [],
   "source": [
    "d2={'b':3,'c':5}"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:01:25.815280600Z",
     "start_time": "2023-06-17T07:01:25.768258800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "outputs": [],
   "source": [
    "res = d1"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:01:34.028028100Z",
     "start_time": "2023-06-17T07:01:34.012395300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "outputs": [],
   "source": [
    "res.update(d2)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:01:40.085898700Z",
     "start_time": "2023-06-17T07:01:40.054475200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "outputs": [
    {
     "data": {
      "text/plain": "{'a': 1, 'b': 3, 'c': 5}"
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:01:41.884199100Z",
     "start_time": "2023-06-17T07:01:41.868573800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "outputs": [],
   "source": [
    "d3={'b':'','a':10}"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:02:58.164789900Z",
     "start_time": "2023-06-17T07:02:58.133365Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "outputs": [],
   "source": [
    "res.update(d3)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:03:05.886500Z",
     "start_time": "2023-06-17T07:03:05.886500Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "outputs": [
    {
     "data": {
      "text/plain": "{'a': 10, 'b': '', 'c': 5}"
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-17T07:03:08.766177500Z",
     "start_time": "2023-06-17T07:03:08.750455400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
